Indian Agency Fines Ranbaxy Unit For Late Lab Report After Patient Death
This article was originally published in PharmAsia News
An Indian agency ordered Ranbaxy Laboratories to pay a fine of $1,165 to an Indian family for failing to issue a test report on time. The fine was ordered by the Delhi State Consumer Disputes Redressal Commission against Specialty Ranbaxy to pay the family after a member died awaiting a crucial medical test needed before surgery. The court said Ranbaxy took 25 days to produce the report, after the patient had died. Conflicting pathological laboratory results led to the request from Specialty Ranbaxy's lab. (Click here for more
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.